Sol-Gel Technologies is an experienced dermatology company developing advanced treatments for patients with rare skin conditions.

Sol-Gel is seeking to expand its pipeline of dermatological drug products by acquiring proven drug candidates. We are also open to opportunities to license out our proprietary assets.

3 days ago · Sol-Gel was successful in developing pioneer topical drugs, Twyneo® and Epsolay®, for the treatment of acne and inflammatory lesions of rosacea. Both products are …

Jul 15, 2024 · Sol-Gel Technologies, Ltd. is a dermatology company focused on identifying, developing, and commercializing or partnering drug products to treat skin diseases. Sol-Gel …

Jan 27, 2023 · Sol-Gel broadens its pipeline with this new chemical entity, designated as investigational compound SGT-610, which has the potential to be the first-ever drug for …

Sol-Gel Technologies is an experienced dermatology company that is leveraging innovative approaches to develop advanced treatments for patients with severe skin conditions.

Sol-gel.com. July 27, 2021. Accessed August 22, 2023. https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-technologies-announces-fda-approval-twyneor.

Apr 17, 2025 · Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, …

Our focus lies on skin diseases that demand therapeutic innovation. By pushing the boundaries of medical dermatology, we strive to bridge the gap between existing treatments and the …

Jun 30, 2025 · Sol-Gel reported a net income of $11.6 million for the second quarter of 2025 and earnings of $4.17 per basic and diluted share, compared to a net loss of $1.9 million and …